VIATRIS INC. Business Acquisition, Pro Forma Revenue
VIATRIS INC. (VTRS) reported Business Acquisition, Pro Forma Revenue of $15.43 billion for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-02-26
- VIATRIS INC. business acquisition, pro forma revenue for the quarter ending 2022-12-31 was $3.88B.
- VIATRIS INC. business acquisition, pro forma revenue for the quarter ending 2022-09-30 was $4.08B.
- VIATRIS INC. business acquisition, pro forma revenue for the quarter ending 2022-06-30 was $4.12B.
- VIATRIS INC. business acquisition, pro forma revenue for fiscal 2023 was $15.43B, a 5.26% decline from fiscal 2022.
- VIATRIS INC. business acquisition, pro forma revenue for fiscal 2022 was $16.28B.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2023-12-31 | $15.43B 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $3.88B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.97B derived: sum of 2 quarters · filed 2025-02-27 | $12.09B derived: sum of 3 quarters · filed 2025-02-27 | $16.28B 10-K · filed 2025-02-27 |
| 2022-09-30 | $4.08B 10-Q · filed 2023-11-08 | $8.21B derived: sum of 2 quarters · filed 2023-11-08 | $12.40B 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $4.12B 10-Q · filed 2023-08-07 | $8.32B 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |